课题基金 / 基金详情

Novel Biomarkers for the Clinical Management of Bladder Cancer

Novel Biomarkers for the Clinical Management of Bladder Cancer
用于膀胱癌临床管理的新型生物标志物
批准号:
10461807
负责人:
Vinata B Lokeshwar
金额:
$44.52万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2018
资助国家:
美国
项目状态:
已结题
起止时间:
2018-07-13 至 2024-06-30
关键词:
AdjuvantBenignBiological MarkersBladderBladder NeoplasmBlindedCancer PatientChemoresistanceChemotherapy-Oncologic ProcedureChondroitin Sulfate ProteoglycanChondroitinasesCisplatinClinicClinicalClinical ManagementCystectomyCystoscopyCytologyDiagnosisDiagnosticDiseaseDisease ProgressionEarly DiagnosisEarly InterventionEnzyme-Linked Immunosorbent AssayEnzymesEvaluationExcisionFDA approvedFamilyFutureGenesGenitourinary systemGlycosaminoglycansGoalsGrowthHematuriaHumanImmunohistochemistryInfectionInvadedLaboratoriesLongitudinal prospective studyMalignant - descriptorMalignant NeoplasmsMalignant neoplasm of urinary bladderMeasuresMessenger RNAMicroscopicMonitorMorbidity - disease rateMuscle DevelopmentNamesNeoplasm MetastasisNon-Invasive Cancer DetectionOperative Surgical ProceduresOutcomePainPainlessPatientsPersonsPilot ProjectsPositive Test ResultProceduresProspective StudiesRNA SplicingRecurrenceResearch DesignResistanceRetrospective StudiesRiskRisk FactorsSpecificitySpecimenSpottingsSymptomsTest ResultTestingTissuesUrineUrographyUrothelial CellValidationVariantaccurate diagnosisbasecancer diagnosiscancer recurrencechemotherapyclinical practicecostdesigndetrusor musclediagnosis evaluationefficacy testingfollow-upgemcitabineimprovedindividualized medicinemembermortalitymuscle invasive bladder cancernoninvasive diagnosisnovelnovel markerpredict clinical outcomepredicting responseprognosticpublic health relevancerate of changeresponsetissue biomarkerstreatment responsetumortumor growthurologicvalidation studies

项目摘要

项目成果

Vinata B Lokeshwar的其他基金

相似基金

相关文献

中文摘要
翻译
摘要:目前临床应用有创诊断法,膀胱术后复发频繁。 肿瘤切除和肌肉浸润性膀胱癌(MIBCA)的高转移倾向有助于 与膀胱癌(BCA)相关的显著发病率和死亡率;是 临床管理。无痛性血尿是BCA患者常见的临床表现。然而,只有 15%-25%的可见血尿患者和约10%的镜检血尿患者实际上 做BCA。出现血尿的患者接受尿路检查,包括膀胱镜检查和CT检查。 尿路造影术。膀胱镜检查是侵入性的和不舒服的,这两种检查都有相当大的风险。 这是一种发病率高、成本高的疾病。频繁的BCA复发需要每3至6个月进行一次膀胱镜检查。 非侵入性生物标志物,包括尿细胞学,可以减少患者的侵入性和昂贵的检查 对于有血尿的患者或正在监测BCA复发的患者。然而,现有的生物标志物是 由于其疗效不佳和/或假阳性率高,未在临床上使用。此外,生物标记物不是 用于预测膀胱切除手术后转移或治疗反应方面的临床结果。 在试点研究中,两种新的非侵入性检测基于糖胺聚糖家族的一种新成员, 对BCA的检测准确率高,对BCA的分级无创评估和早期检测 复发。BCA组织中的生物标记物水平与临床结果相关。本项目旨在评估 假设这两种尿检方法可以准确诊断胆囊癌并对其分级进行无创性评估。 因血尿需要做尿路检查或监测BCA复发的患者。此外,基于组织的 生物标记物可准确预测临床结果。 这两种尿检的有效性将被用来评估BCA的诊断及其分级。 因血尿而接受尿路检查的患者(目标1)。这些尿液测试的有效性将与 监测BCA复发的患者的膀胱镜检查结果。测试的结果也将是 评估以预测未来复发(目标2)。生物标记物在BCA组织中的表达将被检测 用于预测MIBCa的发展、转移和总体临床结局(Aim3)。 影响:这项研究可能会产生两种有效的尿液检测方法,用于无创、准确地检测BCA 作为一项额外的福利进行等级评估。这可以大大减少接受治疗的患者数量。 血尿的泌尿检查或监测BCA复发的膀胱镜检查。组织生物标志物, 如果被发现是准确的预测指标,可以减少MIBCa不必要的侵入性膀胱再切除, 协助晚期BCA患者的早期干预和个体化治疗。总体而言,如果有效, 这些生物标记物可以降低BCA相关的发病率和成本,同时及早改善临床结果。 预测。
英文摘要
ABSTRACT: The current clinical practice of invasive diagnostic workup, frequent recurrence following bladder tumor resection, and high propensity of muscle invasive bladder cancer (MIBCa) for metastasis, contribute to the significant morbidity and mortality associated with bladder cancer (BCa); one of the costliest cancer to manage clinically. Painless hematuria is the common presenting symptom among BCa patients. However, only 15-25% of patients with visible hematuria and about 10% of the patients with microscopic hematuria actually have BCa. Patients presenting with hematuria undergo urological workup that involves cystoscopy and CT- urography. Cystoscopy is invasive and uncomfortable and both procedures associate with considerable risk for morbidity and are costly. Frequent BCa recurrence requires surveillance by cystoscopy every 3 to 6 months. Non-invasive biomarkers, including urine cytology, can reduce the invasive and costly workup among patients with hematuria or for those under surveillance for monitoring BCa recurrence. However, existing biomarkers are not used in clinic due to their sub-optimal efficacy and/or high false-positive rate. Further, biomarkers are not used for predicting clinical outcome in terms of metastasis or treatment response after a bladder removal surgery. In pilot studies, two new non-invasive tests based on a novel member of a glycosaminoglycan family, showed high accuracy to detect BCa, for non-invasively evaluating its grade and for early detection of BCa recurrence. Biomarker levels in BCa tissues correlated with clinical outcome. This project is designed to evaluate a hypothesis that this two urine tests can accurately diagnose BCa and non-invasively evaluate its grade among patients needing urological workup for hematuria, or to monitor BCa recurrence. Furthermore the tissue-based biomarkers accurately predict clinical outcome. The efficacy of both urine tests will be evaluated for BCa diagnosis and for evaluation of its grade among patients undergoing urological workup for hematuria (Aim 1). Efficacy of these urine tests will be compared to cystoscopy findings in patients under surveillance for monitoring BCa recurrence. The tests’ findings will also be evaluated for predicting future recurrence (Aim 2). The biomarkers’ expression in BCa tissues will be examined for predicting the development of MIBCa, metastasis and overall clinical outcome (Aim3). Impact: The study may result in two validated urine tests for non-invasively and accurately detecting BCa with grade evaluation as an added benefit. This could substantially reduce the number of patients undergoing urological workup for hematuria or surveillance cystoscopies for monitoring BCa recurrence. Tissue biomarkers, if found to be accurate prognosticators, could reduce unnecessary invasive bladder re-resections for MIBCa, and aid in early intervention and individualized treatment for patients with advanced BCa. Overall, if efficacious, these biomarkers could reduce BCa-related morbidity, and costs, while improving clinical outcome by early predictions.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Biomarker guided combinations for treating high-risk bladder cancer
  • 批准号:
    10718874
  • 项目类别:
  • 资助金额:
    $55.7万
  • 财政年份:
    2023
  • 负责人:
    Vinata B Lokeshwar
  • 依托单位:
Novel Biomarkers for the Clinical Management of Bladder Cancer
  • 批准号:
    10198863
  • 项目类别:
  • 资助金额:
    $1.57万
  • 财政年份:
    2018
  • 负责人:
    Vinata B Lokeshwar
  • 依托单位:
Novel Biomarkers for the Clinical Management of Bladder Cancer
  • 批准号:
    10659210
  • 项目类别:
  • 资助金额:
    $42.98万
  • 财政年份:
    2018
  • 负责人:
    Vinata B Lokeshwar
  • 依托单位:
Role of CYP3A4 in Prostate Cancer
海外基金